US20220144833A1 - Imidazoquinoline derivatives and their use in therapy - Google Patents
Imidazoquinoline derivatives and their use in therapy Download PDFInfo
- Publication number
- US20220144833A1 US20220144833A1 US17/582,176 US202217582176A US2022144833A1 US 20220144833 A1 US20220144833 A1 US 20220144833A1 US 202217582176 A US202217582176 A US 202217582176A US 2022144833 A1 US2022144833 A1 US 2022144833A1
- Authority
- US
- United States
- Prior art keywords
- compound
- compounds
- compound according
- alkyl
- ifn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 title abstract description 13
- 238000002560 therapeutic procedure Methods 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 146
- 150000003839 salts Chemical class 0.000 claims description 23
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000003282 alkyl amino group Chemical group 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 239000012646 vaccine adjuvant Substances 0.000 abstract description 8
- 229940124931 vaccine adjuvant Drugs 0.000 abstract description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 102
- 238000000034 method Methods 0.000 description 79
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 72
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 47
- 238000003556 assay Methods 0.000 description 44
- 230000000052 comparative effect Effects 0.000 description 41
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 40
- 239000011541 reaction mixture Substances 0.000 description 35
- 102000045715 human TLR7 Human genes 0.000 description 34
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 31
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 31
- 239000000741 silica gel Substances 0.000 description 31
- 229910002027 silica gel Inorganic materials 0.000 description 31
- 238000004587 chromatography analysis Methods 0.000 description 30
- 102000045720 human TLR8 Human genes 0.000 description 30
- 239000000203 mixture Substances 0.000 description 30
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 28
- 230000001939 inductive effect Effects 0.000 description 28
- 239000000556 agonist Substances 0.000 description 27
- 239000000427 antigen Substances 0.000 description 27
- 108091007433 antigens Proteins 0.000 description 27
- 102000036639 antigens Human genes 0.000 description 27
- 102000006992 Interferon-alpha Human genes 0.000 description 25
- 108010047761 Interferon-alpha Proteins 0.000 description 25
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 24
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 23
- 230000003389 potentiating effect Effects 0.000 description 23
- 230000000694 effects Effects 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 20
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 19
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 19
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 19
- 238000009938 salting Methods 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 16
- 0 [1*]c1ccc2c(c1)nc(N)c1nc([2*])n([3*])c12 Chemical compound [1*]c1ccc2c(c1)nc(N)c1nc([2*])n([3*])c12 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 102100037850 Interferon gamma Human genes 0.000 description 15
- 108010074328 Interferon-gamma Proteins 0.000 description 15
- 230000006698 induction Effects 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 239000004381 Choline salt Substances 0.000 description 13
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 13
- 235000019417 choline salt Nutrition 0.000 description 13
- 238000000746 purification Methods 0.000 description 13
- 150000003248 quinolines Chemical class 0.000 description 13
- 238000005160 1H NMR spectroscopy Methods 0.000 description 12
- 241000124008 Mammalia Species 0.000 description 12
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 11
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 11
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 10
- 102000002689 Toll-like receptor Human genes 0.000 description 10
- 108020000411 Toll-like receptor Proteins 0.000 description 10
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 238000010626 work up procedure Methods 0.000 description 9
- 238000001035 drying Methods 0.000 description 8
- DQKGOGJIOHUEGK-UHFFFAOYSA-M hydron;2-hydroxyethyl(trimethyl)azanium;carbonate Chemical group OC([O-])=O.C[N+](C)(C)CCO DQKGOGJIOHUEGK-UHFFFAOYSA-M 0.000 description 8
- 239000003960 organic solvent Substances 0.000 description 8
- 229960005486 vaccine Drugs 0.000 description 8
- HMBHAQMOBKLWRX-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-3-carboxylic acid Chemical class C1=CC=C2OC(C(=O)O)COC2=C1 HMBHAQMOBKLWRX-UHFFFAOYSA-N 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 125000002252 acyl group Chemical group 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 description 7
- -1 methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy, sec-butoxy Chemical group 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 6
- 150000001204 N-oxides Chemical class 0.000 description 6
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 6
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 210000004443 dendritic cell Anatomy 0.000 description 6
- 230000003308 immunostimulating effect Effects 0.000 description 6
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 6
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 description 5
- 229940075419 choline hydroxide Drugs 0.000 description 5
- 238000010511 deprotection reaction Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 229960002751 imiquimod Drugs 0.000 description 5
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 239000008135 aqueous vehicle Substances 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 125000001183 hydrocarbyl group Chemical group 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 239000012442 inert solvent Substances 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 229950010550 resiquimod Drugs 0.000 description 4
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- XUXVVQKJULMMKX-UHFFFAOYSA-N 1,1,1-trimethoxypentane Chemical compound CCCCC(OC)(OC)OC XUXVVQKJULMMKX-UHFFFAOYSA-N 0.000 description 3
- AFSHUZFNMVJNKX-LLWMBOQKSA-N 1,2-dioleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCC\C=C/CCCCCCCC AFSHUZFNMVJNKX-LLWMBOQKSA-N 0.000 description 3
- JNJFONBBNLVENC-UHFFFAOYSA-N 1h-imidazole;trifluoromethanesulfonic acid Chemical compound C1=CNC=N1.OS(=O)(=O)C(F)(F)F JNJFONBBNLVENC-UHFFFAOYSA-N 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 102000013462 Interleukin-12 Human genes 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 3
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 229940124614 TLR 8 agonist Drugs 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000013011 aqueous formulation Substances 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 2
- RKVHNYJPIXOHRW-UHFFFAOYSA-N 3-bis[di(propan-2-yl)amino]phosphanyloxypropanenitrile Chemical compound CC(C)N(C(C)C)P(N(C(C)C)C(C)C)OCCC#N RKVHNYJPIXOHRW-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000709721 Hepatovirus A Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- 229910019213 POCl3 Inorganic materials 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical class N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 210000000182 cd11c+cd123- dc Anatomy 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000000935 solvent evaporation Methods 0.000 description 2
- 238000011146 sterile filtration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- ASAADZNSXOCOCZ-MXSWDONDSA-N (2s,3s,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-3,4-dihydroxyoxolane-2-carboxylic acid Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H]1O ASAADZNSXOCOCZ-MXSWDONDSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- JUGRTVJQTFZHOM-UHFFFAOYSA-N 1,1,1-tribromo-2-methylpropan-2-ol Chemical compound CC(C)(O)C(Br)(Br)Br JUGRTVJQTFZHOM-UHFFFAOYSA-N 0.000 description 1
- JEJLGIQLPYYGEE-XIFFEERXSA-N 1,2-dipalmitoyl-sn-glycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCCCCCCCCCC JEJLGIQLPYYGEE-XIFFEERXSA-N 0.000 description 1
- IQYPSFAWXDKDBA-UHFFFAOYSA-N 1,3-dihydroimidazo[4,5-c]quinolin-2-one Chemical class C1=CC=CC2=C(NC(=O)N3)C3=CN=C21 IQYPSFAWXDKDBA-UHFFFAOYSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- FBFJOZZTIXSPPR-UHFFFAOYSA-N 1-(4-aminobutyl)-2-(ethoxymethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CCCCN)C3=C(N)N=C21 FBFJOZZTIXSPPR-UHFFFAOYSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- ITIRVXDSMXFTPW-UHFFFAOYSA-N 1H-imidazo[4,5-c]quinoline Chemical class C1=CC=CC2=C(NC=N3)C3=CN=C21 ITIRVXDSMXFTPW-UHFFFAOYSA-N 0.000 description 1
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 102100032814 ATP-dependent zinc metalloprotease YME1L1 Human genes 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- KHNMOLRVXBLCGC-UHFFFAOYSA-N C(CCCCCCCC=C/CCCCCCCC)(=O)C(C(C(O)C(CCCCCCCC=C/CCCCCCCC)=O)O)O Chemical compound C(CCCCCCCC=C/CCCCCCCC)(=O)C(C(C(O)C(CCCCCCCC=C/CCCCCCCC)=O)O)O KHNMOLRVXBLCGC-UHFFFAOYSA-N 0.000 description 1
- SVYLUPWEXBUESP-UHFFFAOYSA-M C.C#CC#CC#CC#CC#CC#CC#C.CC#CC#CC#CC#CC#CC.CCCC.CCCCc1nc2c(N)nc3cc(O)ccc3c2n1CCC.CCCCc1nc2c(N)nc3cc(OCCC)ccc3c2n1CCC.CCCCc1nc2c(N)nc3cc(OCCO)ccc3c2n1CCC.O=COO[Cs] Chemical compound C.C#CC#CC#CC#CC#CC#CC#C.CC#CC#CC#CC#CC#CC.CCCC.CCCCc1nc2c(N)nc3cc(O)ccc3c2n1CCC.CCCCc1nc2c(N)nc3cc(OCCC)ccc3c2n1CCC.CCCCc1nc2c(N)nc3cc(OCCO)ccc3c2n1CCC.O=COO[Cs] SVYLUPWEXBUESP-UHFFFAOYSA-M 0.000 description 1
- HWSSVVADSIQQQG-LWLKUQPQSA-N C.C.C#C.CC(C)N(C(C)C)P(OCCC#N)N(C(C)C)C(C)C.CCCCc1nc2c(N)nc3cc(OCCCCO)ccc3c2n1CCC.CCCCc1nc2c(N)nc3cc(OCCCCOP(=O)(O)OC[C@H](C)CC)ccc3c2n1CCO.CCOCNP(OC[C@H](C)CC)N(C(C)C)C(C)C.CC[C@@H](C)CO Chemical compound C.C.C#C.CC(C)N(C(C)C)P(OCCC#N)N(C(C)C)C(C)C.CCCCc1nc2c(N)nc3cc(OCCCCO)ccc3c2n1CCC.CCCCc1nc2c(N)nc3cc(OCCCCOP(=O)(O)OC[C@H](C)CC)ccc3c2n1CCO.CCOCNP(OC[C@H](C)CC)N(C(C)C)C(C)C.CC[C@@H](C)CO HWSSVVADSIQQQG-LWLKUQPQSA-N 0.000 description 1
- YUTWVUKDVYSVOL-ZBXJSEKWSA-N C.C.C#CC.CC(C)N(C(C)C)P(OCCC#N)N(C(C)C)C(C)C.CCCCc1nc2c(N)nc3cc(OCCOCCOCCO)ccc3c2n1CCC.CCCCc1nc2c(N)nc3cc(OCCOCCOCCOP(=O)(O)OC[C@H](C)CC)ccc3c2n1CCO.CCOCNP(OC[C@H](C)CC)N(C(C)C)C(C)C.CC[C@@H](C)CO Chemical compound C.C.C#CC.CC(C)N(C(C)C)P(OCCC#N)N(C(C)C)C(C)C.CCCCc1nc2c(N)nc3cc(OCCOCCOCCO)ccc3c2n1CCC.CCCCc1nc2c(N)nc3cc(OCCOCCOCCOP(=O)(O)OC[C@H](C)CC)ccc3c2n1CCO.CCOCNP(OC[C@H](C)CC)N(C(C)C)C(C)C.CC[C@@H](C)CO YUTWVUKDVYSVOL-ZBXJSEKWSA-N 0.000 description 1
- WIIJPICNFDNYCL-UHFFFAOYSA-M C.C.C.C.C.C.C#C.C#CC#CC#CC.C#CC#CC#CC#CC#C.C#CC#CC#CC#CC#CC.CC#CC#CC#CC#CC#CC.CC(=O)CCC(=O)C(C)(C)C.CCCCC(OC)(OC)OC.CCCCCBr.CCCCCOc1ccc2c(c1)nc(N)c1nc(CCCC)n(CCC)c12.CCCCc1nc2c(N)nc3cc(O)ccc3c2n1CCC.CCCCc1nc2c(N)nc3cc(OCCCCO)ccc3c2n1CCC.CCCCc1nc2c(N)nc3cc(OCCCCO)ccc3c2n1CCO.CCCCc1nc2cnc3cc(C)ccc3c2n1CCC.CCCCc1nc2cnc3cc(C)ccc3c2n1CCO.Cl.O=COO[Cs] Chemical compound C.C.C.C.C.C.C#C.C#CC#CC#CC.C#CC#CC#CC#CC#C.C#CC#CC#CC#CC#CC.CC#CC#CC#CC#CC#CC.CC(=O)CCC(=O)C(C)(C)C.CCCCC(OC)(OC)OC.CCCCCBr.CCCCCOc1ccc2c(c1)nc(N)c1nc(CCCC)n(CCC)c12.CCCCc1nc2c(N)nc3cc(O)ccc3c2n1CCC.CCCCc1nc2c(N)nc3cc(OCCCCO)ccc3c2n1CCC.CCCCc1nc2c(N)nc3cc(OCCCCO)ccc3c2n1CCO.CCCCc1nc2cnc3cc(C)ccc3c2n1CCC.CCCCc1nc2cnc3cc(C)ccc3c2n1CCO.Cl.O=COO[Cs] WIIJPICNFDNYCL-UHFFFAOYSA-M 0.000 description 1
- MKUCOKSRDFVAAG-BZKLDTLHSA-N C.C.C.C.CC(C)N(C(C)C)P(OCCC#N)N(C(C)C)C(C)C.CCCCc1nc2c(N)nc3cc(OCCO)ccc3c2n1CCC.CCCCc1nc2c(N)nc3cc(OCCOP(=O)(O)OCCOCCOCCOC[C@@H](COC(C)=O)OC(C)=O)ccc3c2n1CCO.CCOCNP(OCCOCCOCCOC[C@@H](COC(C)=O)OC(C)=O)N(C(C)C)C(C)C.[H]OCCOCCOCCOC[C@@H](COC(C)=O)OC(C)=O Chemical compound C.C.C.C.CC(C)N(C(C)C)P(OCCC#N)N(C(C)C)C(C)C.CCCCc1nc2c(N)nc3cc(OCCO)ccc3c2n1CCC.CCCCc1nc2c(N)nc3cc(OCCOP(=O)(O)OCCOCCOCCOC[C@@H](COC(C)=O)OC(C)=O)ccc3c2n1CCO.CCOCNP(OCCOCCOCCOC[C@@H](COC(C)=O)OC(C)=O)N(C(C)C)C(C)C.[H]OCCOCCOCCOC[C@@H](COC(C)=O)OC(C)=O MKUCOKSRDFVAAG-BZKLDTLHSA-N 0.000 description 1
- QNYDADFHDJZYPP-BKZLOGBKSA-N C.C.C.CC(=O)OC[C@H](CO)OC(C)=O.CC(=O)OC[C@H](COP(NC(C)C)OCCC#N)OC(C)=O.CC(C)N(C(C)C)P(OCCC#N)N(C(C)C)C(C)C.CCCCc1nc2c(N)nc3cc(OCCO)ccc3c2n1CCC.CCCCc1nc2c(N)nc3cc(OCCOP(=O)(O)OC[C@@H](COC(C)=O)OC(C)=O)ccc3c2n1CCO Chemical compound C.C.C.CC(=O)OC[C@H](CO)OC(C)=O.CC(=O)OC[C@H](COP(NC(C)C)OCCC#N)OC(C)=O.CC(C)N(C(C)C)P(OCCC#N)N(C(C)C)C(C)C.CCCCc1nc2c(N)nc3cc(OCCO)ccc3c2n1CCC.CCCCc1nc2c(N)nc3cc(OCCOP(=O)(O)OC[C@@H](COC(C)=O)OC(C)=O)ccc3c2n1CCO QNYDADFHDJZYPP-BKZLOGBKSA-N 0.000 description 1
- WJMRDSWALUZSDU-KURHFOOFSA-N C.C.C.CC(C)N(C(C)C)P(OCCC#N)N(C(C)C)C(C)C.CCCCc1nc2c(N)nc3cc(OCCO)ccc3c2n1CCC.CCCCc1nc2c(N)nc3cc(OCCOP(=O)(O)OC[C@H](C)CC)ccc3c2n1CCO.CCOCNP(OC[C@H](C)CC)N(C(C)C)C(C)C.CC[C@@H](C)CO Chemical compound C.C.C.CC(C)N(C(C)C)P(OCCC#N)N(C(C)C)C(C)C.CCCCc1nc2c(N)nc3cc(OCCO)ccc3c2n1CCC.CCCCc1nc2c(N)nc3cc(OCCOP(=O)(O)OC[C@H](C)CC)ccc3c2n1CCO.CCOCNP(OC[C@H](C)CC)N(C(C)C)C(C)C.CC[C@@H](C)CO WJMRDSWALUZSDU-KURHFOOFSA-N 0.000 description 1
- WUZUOZLHZAFOHV-QYPZPZMKSA-N C.C.C.CC(C)N(C(C)C)P(OCCC#N)N(C(C)C)C(C)C.CCCCc1nc2c(N)nc3ccccc3c2n1CCO.CCCCc1nc2c(N)nc3ccccc3c2n1CCOP(=O)(O)OC[C@H](C)CC.CCOCNP(OC[C@H](C)CC)N(C(C)C)C(C)C.CC[C@@H](C)CO Chemical compound C.C.C.CC(C)N(C(C)C)P(OCCC#N)N(C(C)C)C(C)C.CCCCc1nc2c(N)nc3ccccc3c2n1CCO.CCCCc1nc2c(N)nc3ccccc3c2n1CCOP(=O)(O)OC[C@H](C)CC.CCOCNP(OC[C@H](C)CC)N(C(C)C)C(C)C.CC[C@@H](C)CO WUZUOZLHZAFOHV-QYPZPZMKSA-N 0.000 description 1
- CUOSMXJNPCFTRJ-UHFFFAOYSA-N C.C.CC(C)N(C(C)C)P(OCCC#N)N(C(C)C)C(C)C.CCCCc1nc2c(N)nc3cc(OCCO)ccc3c2n1CCC.CCCCc1nc2c(N)nc3cc(OCCOP(=O)(O)OCCOCCOCCOC)ccc3c2n1CCO.CCOCNP(OCCOCCOCCOC)N(C(C)C)C(C)C.COCCOCCOCCO Chemical compound C.C.CC(C)N(C(C)C)P(OCCC#N)N(C(C)C)C(C)C.CCCCc1nc2c(N)nc3cc(OCCO)ccc3c2n1CCC.CCCCc1nc2c(N)nc3cc(OCCOP(=O)(O)OCCOCCOCCOC)ccc3c2n1CCO.CCOCNP(OCCOCCOCCOC)N(C(C)C)C(C)C.COCCOCCOCCO CUOSMXJNPCFTRJ-UHFFFAOYSA-N 0.000 description 1
- AYAZYAIRGFXFSC-UHFFFAOYSA-M C.CC#CC#CC#CC#CC#CC.CCCCc1nc2c(N)nc3cc(O)ccc3c2n1CCC.CCCCc1nc2c(N)nc3cc(OCCCCO)ccc3c2n1CCC.O=COO[Cs].OCCOCCOCCBr Chemical compound C.CC#CC#CC#CC#CC#CC.CCCCc1nc2c(N)nc3cc(O)ccc3c2n1CCC.CCCCc1nc2c(N)nc3cc(OCCCCO)ccc3c2n1CCC.O=COO[Cs].OCCOCCOCCBr AYAZYAIRGFXFSC-UHFFFAOYSA-M 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- CZVFSDFQYYUQKN-SUOMESGTSA-N CC/C=C\CC(=O)OC[C@@H](O)COP(=O)(O)OCCOc1ccc2c(c1)nc(N)c1nc(CCCC)n(CCO)c12 Chemical compound CC/C=C\CC(=O)OC[C@@H](O)COP(=O)(O)OCCOc1ccc2c(c1)nc(N)c1nc(CCCC)n(CCO)c12 CZVFSDFQYYUQKN-SUOMESGTSA-N 0.000 description 1
- AZWYFLXQKJQNAD-AMQVECOWSA-N CC/C=C\CC(=O)OC[C@H](COP(=O)(O)OCCCCOc1ccc2c(c1)nc(N)c1nc(CCCC)n(CCO)c12)OC(=O)C/C=C\CC Chemical compound CC/C=C\CC(=O)OC[C@H](COP(=O)(O)OCCCCOc1ccc2c(c1)nc(N)c1nc(CCCC)n(CCO)c12)OC(=O)C/C=C\CC AZWYFLXQKJQNAD-AMQVECOWSA-N 0.000 description 1
- UHWRGDXEUXAOLL-FOLBXWKHSA-N CC/C=C\CC(=O)OC[C@H](COP(=O)(O)OCCOCCOCCOc1ccc2c(c1)nc(N)c1nc(CCCC)n(CCO)c12)OC(=O)C/C=C\CC Chemical compound CC/C=C\CC(=O)OC[C@H](COP(=O)(O)OCCOCCOCCOc1ccc2c(c1)nc(N)c1nc(CCCC)n(CCO)c12)OC(=O)C/C=C\CC UHWRGDXEUXAOLL-FOLBXWKHSA-N 0.000 description 1
- OFZPRNGTYXDQCC-NPCAQMNCSA-N CC/C=C\CC(=O)OC[C@H](COP(=O)(O)OCCOc1ccc2c(c1)nc(N)c1nc(CCCC)n(CCO)c12)OC(=O)C/C=C\CC Chemical compound CC/C=C\CC(=O)OC[C@H](COP(=O)(O)OCCOc1ccc2c(c1)nc(N)c1nc(CCCC)n(CCO)c12)OC(=O)C/C=C\CC OFZPRNGTYXDQCC-NPCAQMNCSA-N 0.000 description 1
- RNBCMKBERICVHW-OLPBEGMFSA-N CC/C=C\CC(=O)OC[C@H](COP(=O)(O)OCCn1c(CCCC)nc2c(N)nc3ccccc3c21)OC(=O)C/C=C\CC Chemical compound CC/C=C\CC(=O)OC[C@H](COP(=O)(O)OCCn1c(CCCC)nc2c(N)nc3ccccc3c21)OC(=O)C/C=C\CC RNBCMKBERICVHW-OLPBEGMFSA-N 0.000 description 1
- AOZYUZXSJPZXIW-UHFFFAOYSA-N CCCCc1nc2c(N)nc3cc(OCCCCO)ccc3c2n1CCO Chemical compound CCCCc1nc2c(N)nc3cc(OCCCCO)ccc3c2n1CCO AOZYUZXSJPZXIW-UHFFFAOYSA-N 0.000 description 1
- MJCSLHCIMFDPLQ-UHFFFAOYSA-N CCCCc1nc2c(N)nc3cc(OCCO)ccc3c2n1CCO Chemical compound CCCCc1nc2c(N)nc3cc(OCCO)ccc3c2n1CCO MJCSLHCIMFDPLQ-UHFFFAOYSA-N 0.000 description 1
- LEPPNWVSIDDWBV-UHFFFAOYSA-N CCCCc1nc2c(N)nc3cc(OCCOCCOCCO)ccc3c2n1CCO Chemical compound CCCCc1nc2c(N)nc3cc(OCCOCCOCCO)ccc3c2n1CCO LEPPNWVSIDDWBV-UHFFFAOYSA-N 0.000 description 1
- DCOMRRVWHVSUPB-UHFFFAOYSA-N CCCCc1nc2c(N)nc3cc(OCCOP(=O)(O)OCCOCCOCCOC)ccc3c2n1CCO Chemical compound CCCCc1nc2c(N)nc3cc(OCCOP(=O)(O)OCCOCCOCCOC)ccc3c2n1CCO DCOMRRVWHVSUPB-UHFFFAOYSA-N 0.000 description 1
- NLNHUJDVBZWGHN-VWLOTQADSA-N CCCCc1nc2c(N)nc3cc(OCCOP(=O)(O)OCCOCCOCCOC[C@@H](COC(C)=O)OC(C)=O)ccc3c2n1CCO Chemical compound CCCCc1nc2c(N)nc3cc(OCCOP(=O)(O)OCCOCCOCCOC[C@@H](COC(C)=O)OC(C)=O)ccc3c2n1CCO NLNHUJDVBZWGHN-VWLOTQADSA-N 0.000 description 1
- WYWURKNJIJGZND-LJQANCHMSA-N CCCCc1nc2c(N)nc3cc(OCCOP(=O)(O)OC[C@@H](COC(C)=O)OC(C)=O)ccc3c2n1CCO Chemical compound CCCCc1nc2c(N)nc3cc(OCCOP(=O)(O)OC[C@@H](COC(C)=O)OC(C)=O)ccc3c2n1CCO WYWURKNJIJGZND-LJQANCHMSA-N 0.000 description 1
- KGUKVKKEISZFRP-UHFFFAOYSA-N CCCCc1nc2c(N)nc3ccccc3c2n1CCO Chemical compound CCCCc1nc2c(N)nc3ccccc3c2n1CCO KGUKVKKEISZFRP-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000595548 Homo sapiens TIR domain-containing adapter molecule 1 Proteins 0.000 description 1
- 101000595554 Homo sapiens TIR domain-containing adapter molecule 2 Proteins 0.000 description 1
- 101000637726 Homo sapiens Toll/interleukin-1 receptor domain-containing adapter protein Proteins 0.000 description 1
- 101000649115 Homo sapiens Translocating chain-associated membrane protein 1 Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 241000430519 Human rhinovirus sp. Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 description 1
- 108010032036 Interferon Regulatory Factor-7 Proteins 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102100038070 Interferon regulatory factor 7 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 101000574441 Mus musculus Alkaline phosphatase, germ cell type Proteins 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- GFHDXMFDYDRBSI-UHFFFAOYSA-N OCCOCCOCCO.Br Chemical compound OCCOCCOCCO.Br GFHDXMFDYDRBSI-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100036073 TIR domain-containing adapter molecule 1 Human genes 0.000 description 1
- 229940124613 TLR 7/8 agonist Drugs 0.000 description 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 102100032120 Toll/interleukin-1 receptor domain-containing adapter protein Human genes 0.000 description 1
- 102100027965 Translocating chain-associated membrane protein 1 Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- ZWELIJXAKMASLK-UGKPPGOTSA-N [(2r,3r,4r,5r)-4-acetyloxy-5-(5-amino-2-oxo-[1,3]thiazolo[4,5-d]pyrimidin-3-yl)-2-(hydroxymethyl)oxolan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1[C@H](OC(=O)C)[C@@H](CO)O[C@H]1N1C(=O)SC2=CN=C(N)N=C21 ZWELIJXAKMASLK-UGKPPGOTSA-N 0.000 description 1
- NWYFNJPZQIBIJF-OWJIYDKWSA-N [(2s)-3-hydroxy-2-(oxan-2-yloxy)propyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](CO)OC1CCCCO1 NWYFNJPZQIBIJF-OWJIYDKWSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000008349 antigen-specific humoral response Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- SQQXRXKYTKFFSM-UHFFFAOYSA-N chembl1992147 Chemical compound OC1=C(OC)C(OC)=CC=C1C1=C(C)C(C(O)=O)=NC(C=2N=C3C4=NC(C)(C)N=C4C(OC)=C(O)C3=CC=2)=C1N SQQXRXKYTKFFSM-UHFFFAOYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- JEJLGIQLPYYGEE-UHFFFAOYSA-N glycerol dipalmitate Natural products CCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCC JEJLGIQLPYYGEE-UHFFFAOYSA-N 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- BICAGYDGRXJYGD-UHFFFAOYSA-N hydrobromide;hydrochloride Chemical compound Cl.Br BICAGYDGRXJYGD-UHFFFAOYSA-N 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical class ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229940124669 imidazoquinoline Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910001412 inorganic anion Inorganic materials 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000010468 interferon response Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002669 linoleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 239000013586 microbial product Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003935 n-pentoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 150000002891 organic anions Chemical class 0.000 description 1
- 229940047091 other immunostimulants in atc Drugs 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 210000005238 principal cell Anatomy 0.000 description 1
- 238000011165 process development Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003527 tetrahydropyrans Chemical group 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Abstract
This invention relates inter alia to novel imidazoquinoline derivatives and their use in therapy, particularly as vaccine adjuvants.
Description
- This application is a Divisional of copending U.S. application Ser. No. 16/330,599, filed on Mar. 5, 2019, which is a National Stage Entry of PCT International Application No. PCT/EP2017/072152 filed on Sep. 5, 2017, which claims the benefit under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 62/384,618, filed on Sep. 7, 2016, all of which are hereby expressly incorporated by reference into the present application.
- This invention was made with Government support under contract #HHSN272200900036C awarded by the National Institutes of Health. The Government has certain rights in the invention.
- The present invention relates to novel imidazoquinoline derivatives, processes for their preparation, compositions containing them, and their use in therapy especially as vaccine adjuvants.
- The refinement and simplification of microbial vaccines and the use of synthetic and recombinant subunit antigens to improve vaccine manufacturability and safety has resulted in a decrease in vaccine potency. This has led to studies on the co-administration of adjuvants with antigens to potentiate vaccine activity and the weak immunogenicity of synthetic and recombinant epitopes. Adjuvants are additives that enhance humoral and/or cell-mediated immune responses to a vaccine antigen. The design of vaccine adjuvants, however, has historically been difficult because of the complex nature of the molecular mechanisms involved in immune system function. Although the addition of microbial components has long been known to enhance adaptive immune responses, only recently was it shown that toll-like receptors (TLRs) on cells involved in immune surveillance, such as epithelial and dendritic cells, engage many of these microbial products via so-called “pathogen-associated patterns” or PAMPs. Many vaccine adjuvants and stand-alone immunomodulators appear to interact with members of the TLR family.
- Of the 10 known TLRs that have been identified in humans, five are associated with the recognition of bacterial components (
TLRs TLRs TLRs - In the case of TLR7 and TLR8 activation, a few different classes of small molecule mimetics of the natural (U- and/or G-rich) viral ssRNA ligands have been identified. These include certain antiviral compounds related to oxidized guanosine metabolites (oxoguanosines), which primarily interact with TLR7 (Heil, F. Eur J Immunol 2003, 33, 2987; Hemmi, 2002) and derivatives of adenine which engage TLR7 and/or TLR8. The immune stimulating ability of these compounds has been attributed to the TLR/MyD88-dependent signaling pathways and the production of cytokines, including IL-6 and type I (particularly interferon-α) and II interferons. TLR7 or TLR8 activation leads to the upregulation of co-stimulatory molecules (e.g. CD-40, CD-80, CD-86) and class I and II MHC molecules on dendritic cells (DCs). DCs are the principal cells of the immune system involved in uptake and presentation of antigens to T lymphocytes. Plasmacytoid dendritic cells (pDCs), which preferentially express TLR7, are professional interferon-α producing cells; whereas mDCs express TLR8 only. TLR8 activation on mDCs leads to the preferential production of pro-inflammatory cytokines such as IL-12, TNF-α, and IFN-γ and cell-mediated immunity (CMI). It has been shown that TLR7 agonists are more effective at generating IFN-α and IFN-regulated cytokines, whereas TLR8 agonists, which lead to the reversal of CD4+ regulatory (Treg) cell function, are more effective at inducing proinflammatory cytokines such as TNF-α and IL-12, suggesting that TLR7 activation may be more important for antibody responses (Th2-type responses) while TLR8 activation should induce CMI or Th1-type immune responses (Gordon J Immunol 2005, 1259).
- One class of TLR-active adenine derivatives that has received a considerable amount of attention are the 1H-imidazo[4,5-c]quinolines. The prototypical member of this class, imiquimod, was found to be effective against genital papilloma virus infections, actinitic keratosis and basal cell carcinoma when applied topically in cream form. Imiquimod, however, has relatively low interferon inducing activity in both oral and topical preparations and both oral and topical preparations are not without side effects. In fact, serious side effects were reported in an HCV clinical trial with imiquimod. The large immunological “footprint” of TLR7 agonists in general has led to concerns over toxicity: clinical trials with another TLR7 agonist ANA-975, an oxoguanosine derivative, were suspended due to toxicity issues.
- Another member of the 1H-imidazo[4,5-c]quinolone class of TLR7/8 ligands is resiquimod. Resiquimod also activates TLR7 in macrophages and DCs in a MyD88-dependent manner either directly or indirectly via an accessory molecule and upregulates co-stimulatory molecules and MHCI/II in DCs. In contrast to imiquimod, the more potent and toxic resiquimod is also a ligand for TLR8 signaling, which leads to the reversal of CD4+ regulatory (Treg) cell function.
- Lipid conjugates of nucleoside drugs are known in the art to enhance oral bioavailability in general as well as to permit incorporation of the resulting “nucleolipid” into lipid membranes of liposomes (Rosemeyer, H. Chemistry & Biodiversity 2005, 2, 977-1063). Incorporating sensitive and/or highly active molecules in liposomes establishes a slow release carrier system or molecular depot which protects the molecule from degradation and decreases toxic side effects. It has often been found, however, that lipid conjugates are less biologically active than the parent molecule.
- Certain lipidated imidazoquinoline derivatives have been described in U.S. Pat. No. 8,624,029 (Johnson) and these compounds have advantages over corresponding unlipidated analogues.
- It remains an objective to discover further effective and safe vaccine adjuvants.
- Herein we describe novel lipidated imidazoquinoline derivatives. The compounds of the invention have been shown to be inducers of cytokines such IFN-α, IFN-γ and TNF-α and to be agonists of TLR7 and/or TLR8. These compounds are expected to be useful as vaccine adjuvants in the therapeutic or prophylactic treatment of inter alia infectious diseases and cancer.
-
FIG. 1 shows a plot of curves of various compounds tested in the hTLR7 agonist reporter assay in HEK293 cells. -
FIG. 2 shows a plot of curves of various compounds tested in the hTLR8 agonist reporter assay in HEK293 cells. -
FIG. 3 shows a plot of curves of various compounds tested in the hTLR7 agonist reporter assay in HEK293 cells. -
FIG. 4 shows a plot of curves of various compounds tested in the hTLR8 agonist reporter assay in HEK293 cells. -
FIG. 5 shows a plot of curves of various compounds tested in the hTLR7 agonist reporter assay in HEK293 cells. -
FIG. 6 shows a plot of curves of various compounds tested in the hTLR8 agonist reporter assay in HEK293 cells. -
FIG. 7 shows a plot of curves of various compounds tested in the hTLR7 agonist reporter assay in HEK293 cells. -
FIG. 8 shows a plot of curves of various compounds tested in the hTLR8 agonist reporter assay in HEK293 cells. -
FIG. 9 shows a plot of curves of various compounds tested in the assay for IFN-γ induction in hPBMCs. -
FIG. 10 shows a plot of curves of various compounds tested in the assay for IFN-α induction in hPBMCs -
FIG. 11 shows a plot of curves of various compounds tested in the assay for IFN-γ induction in hPBMCs. -
FIG. 12 shows a plot of curves of various compounds tested in the assay for IFN-α induction in hPBMCs -
FIG. 13 shows a plot of curves of various compounds tested in the assay for TNF-α induction in hPBMCs -
FIG. 14 shows a plot of curves of various compounds tested in the assay for IFN-α induction in hPBMCs -
FIG. 15 shows a plot of curves of various compounds tested in the assay for TNF-α induction in hPBMCs -
FIG. 16 shows a plot of curves of various compounds tested in the assay for IFN-α induction in hPBMCs -
FIG. 17 shows a plot of curves of various compounds tested in the assay for TNF-α induction in hPBMCs -
FIG. 18 shows a schematic representation of salting methods, as described herein. - Throughout this application, references are made to various embodiments relating to compounds, compositions, and methods. The various embodiments described are meant to provide a variety of illustrative examples and should not be construed as descriptions of alternative species. Rather it should be noted that the descriptions of various embodiments provided herein may be of overlapping scope. The embodiments discussed herein are merely illustrative and are not meant to limit the scope of the present invention.
- It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present invention. In this specification and in the claims that follow, reference will be made to a number of terms that shall be defined to have the following meanings.
- “Alkyl” refers to monovalent saturated aliphatic hydrocarbyl groups having, according to various embodiments, up to 24 carbon atoms and, in some embodiments, from 1 to 6 carbon atoms and, in further embodiments, from 2 to 6 carbon atoms. “(Cx-Cy)alkyl” refers to alkyl groups having from x to y carbon atoms. This term includes, by way of example, linear and branched hydrocarbyl groups such as methyl (CH3—), ethyl (CH3CH2—), n-propyl (CH3CH2CH2—), isopropyl ((CH3)2CH—), n-butyl (CH3CH2CH2CH2—), isobutyl ((CH3)2CHCH2—), sec-butyl ((CH3)(CH3CH2)CH—), t-butyl ((CH3)3C—), n-pentyl (CH3CH2CH2CH2CH2—), and neopentyl ((CH3)3CCH2—).
- “Alkylene” means a divalent saturated aliphatic hydrocarbyl groups having, according to various embodiments, from 2 to 6 carbon atoms. This term includes, by way of example, linear and branched hydrocarbyl groups such as ethylene (—CH2CH2—), n-propylene (—CH2CH2CH2—), isopropylene (—CH(CH3)CH—), n-butylene (—CH2CH2CH2CH2—), isobutylene (—CH(CH3)CHCH2—), sec-butylene (CH(CH3CH2)CH—) and n-pentylene (—CH2CH2CH2CH2CH2—).
- “Alkoxy” refers to the group —O-alkyl wherein alkyl is defined herein. Alkoxy includes, by way of example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy, sec-butoxy, and n-pentoxy.
- “Amino” refers to the group —NHR6 where R6 is independently selected from hydrogen, C1-6 alkyl and C2-6 alkenyl, and typically represents H or Me. However, the expression C1-C6alkylamino means (C1-C6 alkyl)HN—, the expression C3-C6 cycloalkylC1-C6 alkylamino means (C3-C6 cycloalkyl)(C1-C6 alkyl)N— and the expression C1-C6 alkoxyC1-C6 alkylamino means (C1-C6 alkoxy)(C1-C6 alkyl)N—.
- “Cycloalkyl” refers to a saturated carbocyclic group of from 3 to 14 carbon atoms (e.g. from 3 to 8 carbon atoms, particularly 3 to 6 carbon atoms) and no ring heteroatoms. “Cycloalkenyl” refers to an unsaturated carbocyclic group of from 5 to 14 carbon atoms (e.g. from 6 to 8 carbon atoms, such as 6 or 7 carbon atoms) and no ring heteroatoms and containing at least one ring carbon carbon double bond.
- “Alkenyl” refers to an unsaturated alkyl group which contains at least one carbon-carbon double bond. For example it may contain one, two or three double bonds but more typically will contain 2 or most usually one double bond.
- Unless indicated otherwise, the nomenclature of substituents that are not explicitly defined herein are arrived at by naming the terminal portion of the functionality followed by the adjacent functionality toward the point of attachment. For example, the substituent “C3-C6cycloalkylC1-C6alkoxy” refers to the group (C3-C6cycloalkyl)-(C1-C6alkoxy)-, It is understood that the above definitions are not intended to include impermissible substitution patterns (e.g., methyl substituted with 5 fluoro groups). Such impermissible substitution patterns are well known to the skilled artisan.
- The compounds of the subject invention are described generally by formula (I):
- wherein:
R1 represents —O—Z—(P(═O)—OH)—O—Y—A
R2 represents H, C1-C6 alkyl, C1-C6alkylamino, C1-C6alkoxy, C3-C6 cycloalkylC1-C6 alkyl,
C3-C6 cycloalkylC1-C6 alkylamino, C3-C6 cycloalkylC1-C6 alkoxy, C1-C6 alkoxyC1-C6 alkyl,
C1-C6 alkoxyC1-C6 alkylamino, C1-C6 alkoxyC1-C6 alkoxy; and optionally terminally substituted with a hydroxyl, amino, —NHNH2, N3, —C≡CH, —COOH, or maleimido group;
Z represents (C2-C6 alkyleneO)q;
Y represents (C2-C6alkyleneO)r;
q represents aninteger 1 to 6;
r represents 0 or aninteger 1 to 20;
R3 represents C2-C6 alkylene-OH, C2-C6 alkylene-NH2, C2-C5 alkenyl-CH2—OH or C2-C5 alkenyl-CH2—NH2; - A represents
- wherein:
- R4 represents H, C4-C24 alkyl, C4-C24 alkenyl, —CO-C3-C23 alkyl, or —CO-C3-C23 alkenyl;
- R5 represents, C4-C24 alkyl, C4-C24 alkenyl, —CO-C3-C23 alkyl, or —CO-C3-C23 alkenyl;
- p represents 0 or an
integer 1 to 6; - or a pharmaceutically acceptable salt thereof.
- Suitably R2 represents H, C1-C6 alkyl or C1-C6 alkoxyC1-C6 alkyl, especially H, C1-C6 alkyl or C1-C3 alkoxyC1-C3 alkyl. For example, R2 represents H, n-butyl or —CH2OCH2CH3 especially n-butyl.
- Suitably q represents an
integer 1 to 3, particularly 1 or 3 and especially 1. - Suitably r represents 0 or an
integer 1 to 6 e.g. 0 or aninteger 1 to 3, such as 0 or 3 especially 0. - Suitably R3 represents C2-C6 alkylene-OH or C2-C6 alkylene-NH2, particularly C2-C6 alkylene-OH and especially CH2CH2OH.
- Suitably p represents an
integer 1 to 3. - Suitably A represents
- In one preferred embodiment, the compounds of the subject invention are described generally by formula (IA):
- wherein:
R1 represents —O—Z—(P(═O)—OH)—O—Y—A
R2 represents H, C1-C6 alkyl or C1-C3 alkoxyC1-C3 alkyl;
Z represents (C2-C6 alkyleneO)q;
Y represents (C2-C6 alkyleneO)r;
q represents aninteger 1 to 6;
r represents 0 or aninteger 1 to 20;
R3 represents C2-C6 alkylene-OH;
A represents - wherein:
- R4 represents H, —CO-C3-C23 alkyl, or —CO-C3-C23 alkenyl;
- R5 represents, —CO-C3-C23 alkyl, or —CO-C3-C23 alkenyl;
- or a pharmaceutically acceptable salt thereof.
- Suitably R2 represents H, n-butyl or CH3CH2OCH2— especially n-butyl.
- Suitably Z represents ((CH2)2O)q especially CH2CH2O or Z represents CH2CH2CH2CH2O, especially CH2CH2O.
- Suitably Y represents ((CH2)2O)r.
- Suitably q represents an
integer 1 to 3, particularly 1 or 3 and especially 1. - Suitably r represents 0 or an
integer 1 to 6 e.g. 0 or aninteger 1 to 3, such as 0 or 3 especially 0. - Suitably R3 represents —CH2CH2OH.
- In one embodiment R4 represents H and R5 represents —CO-C3-C23 alkyl, or —CO-C3-C23 alkenyl. In an alternative embodiment, R4 and R5 independently represent —CO-C3-C23 alkyl or —CO-C3-C23 alkenyl.
- Suitably R4 and R5 independently represent lauroyl, myristoyl, palmitoyl, oleoyl or linoleoyl, preferably oleoyl or palmitoyl, especially oleoyl. Suitably R4 and R5 are the same.
- The compounds of the subject invention may be prepared by reaction of a compound of formula (II):
- wherein:
R1a represents —O—Z—H;
and Z, R2 and R3 are defined as for compounds of Formula (I);
or a protected derivative thereof;
with a compound of formula (III) -
Pg—OP(N-iPr2)—O—Y—A (III) - wherein A is defined as for compounds of Formula (I) and Pg is a protecting group, typically CNCH2CH2—, followed by oxidation of P(III) to P(V) and removal of protecting groups.
- Conditions suitable for performing this reaction include combining the ingredients in the presence of imidazolium triflate (Imid-OTf) in an inert organic solvent such as CH2Cl2. The reaction product can be purified or directly oxidized followed by removal of protecting groups.
- Suitably the hydroxyl group of R3 is protected by an acyl group, such as a levulinoyl group. Deprotection may be achieved by treatment with hydrazine.
- When R4 represents hydrogen, it may be protected as an ether e.g. with tetrahydropyran (THP). This group may be removed at the desired stage by treatment with acid (e.g. HCl).
- Compounds of formula (II) or a protected derivative thereof may be prepared by reaction of a compound of formula (IV)
- wherein:
R2 and R3 are defined as for compounds of formula (I);
or a protected derivative thereof;
with a compound of formula (V) -
L1—ZH (V) - wherein Z is as defined as for compounds of formula (I) and L1 is a leaving group or a protected derivative thereof.
- Example leaving groups L1 include halogen such as Br, mesylate, tosylate and the like, especially Br.
- Typically the compound of formula (V) will be employed in a form in which the terminal hydroxyl of group Z is protected. Suitable hydroxyl protecting groups include acyl groups such as acetyl or as silyl ethers such as the t-butyldimethylsilyl (TBS) ether, or as ether such as benzyl (Bn) ether.
- Conditions for the reaction of compounds of formulae (IV) and (V) include combining the reagents in the presence of cesium carbonate in an organic solvent such as DMF followed by aqueous work-up and purification.
- Alternatively, compounds of formula (II) or protected derivatives thereof may be prepared by heating a compound of formula (VI)
- wherein:
R1a represents —O—Z—H;
and Z, R2 and R3 are defined as for compounds of formula (I) or a protected derivative thereof with an oxidising agent such as CH2CO3H or 3-chloro-peroxybenzoic acid in an inert solvent such as ethanol or methylene chloride to form an N-oxide followed by reaction to form an activated ester e.g.
with pTsCl or methanesulfonyl chloride in an inert solvent such as methylene chloride followed by amination with ammonia or an ammonia derivative such as NH4OH in an inert solvent such as methylene chloride. The reaction also proceeds if the N-oxide is treated with the ammonia or ammonia derivative prior to the pTsCl or methanesulfonyl chloride (or other reagent to form an activated ester). - Suitably the hydroxyl group of R3 is protected by an acyl group, such as a levulinoyl group. Deprotection may be achieved by treatment with hydrazine.
- Further details of this conversion may be gleaned by reference to WO05/020999 (the contents of which are herein incorporated by reference in their entirety) and particularly
Reaction Scheme 1 where similar processes are described. - Compounds of formula (VI) or a protected derivative thereof may be prepared by reaction of a compound of formula (VII)
- wherein:
and R2 and R3 are defined as for compounds of formula (I);
or a protected derivative thereof;
with a compound of formula (V) -
L1—-ZH (V) - wherein Z is as defined as for compounds of Formula (I) and L1 is a leaving group or a protected derivative thereof.
- Typically the compound of formula (V) will be employed in a form in which the terminal hydroxyl of group Z is protected. Suitable hydroxyl protecting groups include esters formed from acyl groups such as acetyl or as silyl ethers such as the t-butyldimethylsilyl (TBS) ether or as ether such as benzyl (Bn) ether.
- A suitable leaving group L1 is halogen such as Br, mesylate, tosylate and the like, especially Br.
- Exemplary conditions for this reaction are the same as those for the reaction of compounds of formula (IV) and (V).
- Suitably the hydroxyl group of R3 is protected by an acyl group, such as a levulinoyl group. Deprotection may be achieved by treatment with hydrazine.
- Suitably the phenolic hydroxyl group is protected as an ether group e.g. as the benzyl ether. Deprotection may be achieved by reduction e.g. with H2 gas over Pd/C.
- The synthesis of compounds of formula (IV) and (VII) and protected derivatives thereof is illustrated in Scheme 1 below:
- Suitably L2 is halogen, especially Cl.
- Further details of conversions shown in
Scheme 1 may be gleaned by reference to WO05/020999 (the contents of which are herein incorporated by reference in their entirety) and particularlyReaction Scheme 1 where similar processes are described. - Compounds of formula (III) or a protected derivative thereof may be prepared by reacting a compound of formula (VIII)
-
H—O—Y—A (VIII) - with a compound of formula (IX)
-
PgOP(N-iPr2)2 (IX) - and Pg is a protecting group, typically CNCH2CH2—.
- Conditions for the reaction of compounds of formula (VIII) and (IX) include combining the reagents in an inert solvent such as CH2Cl2 in the presence of tetrazole or other coupling reagent known in the art.
- Intermediate compounds of formula (II) and (VI) are new and are claimed as an aspect of the invention. As noted in the examples, compounds of formula (II) and (IV) may have at least some of the biological activity of compounds of formula (I).
- Thus the invention provides compound of formula (II):
- wherein:
- R1a represents —O—Z—H;
- and Z, R2 and R3 are defined as per compounds of formula (I) and (IA);
- or a protected derivative thereof.
- The invention also provides a compound of formula (VI)
- wherein:
- R1a represents —O—Z—H;
- and Z, R2 and R3 are defined as per compounds of formula (I) and (IA);
- or a protected derivative thereof.
- In compounds of formula (II), (IV), (VI) and (VII) alcohol groups may be protected as an ester e.g. by reaction with an acyl group (e.g. acetyl or levulinoyl) or may be protected as an ether e.g. as an ether formed with THP or benzyl.
- In compounds of formula (II), (IV), (VI) and (VII) amine groups may be protected as an amide e.g. by reaction with an acyl group (e.g. acetyl or levulinoyl).
- Compounds of formula (V), (VIII) and (IX) are known or may be prepared by known methods.
- The starting compounds and other reagents shown in
Scheme 1 are known or may be prepared by known methods. - Pharmaceutically acceptable salts of the compounds of the invention may include acid salts formed with
group 1 metal cations (such as sodium and potassium ions) andgroup 2 metal cations (such as calcium and magnesium ions) as well as with inorganic cations such as ammonium ion or other quarternary ammonium ions (such as choline) and basic salts formed with inorganic anions such as halide (e.g. chloride bromide), phosphate and sulfate and organic anions (e.g. mesylate, succinate, maleate and acetate). Preferred salts are salts formed with choline. In specific embodiments, the salt is a choline bicarbonate salt or a choline hydroxide salt. - The invention also provides methods for making pharmaceutically acceptable salts of a lipidated imidazoquinoline derivative compound. In one embodiment, such salting methods include a method of preparing a choline salt of a lipidated imidazoquinoline derivative, comprising:
- (a) dissolving the compound in an aqueous vehicle;
- (b) adding the choline salt; and
- (c) mixing the compound and choline salt,
- wherein, the method does not include the use of an organic solvent. In some embodiments, the method does not include a drying step.
- In another embodiment, salting methods of the invention include a method of preparing a choline salt of a lipidated imidazoquinoline derivative, comprising:
- (a) dissolving the compound in an organic solvent;
- (b) adding the choline salt;
- (c) mixing the compound and choline salt,
- (d) removing the organic solvent to produce a dried salt, and
- (e) dissolving the dried salt in an aqueous vehicle;
- wherein the method does not include a vacuum drying step. In one embodiment, the organic solvent used in the salting method is tetrahydrofuran (THF). In an additional embodiment, the choline salt is selected from choline bicarbonate and choline hydroxide.
- In some embodiments, the lipidated imidazoquinoline derivative is a lipidated imidazoquinoline derivative described herein. In some embodiments, the aqueous vehicle used in the salting methods of the invention is water, optionally containing glycerol (e.g., 1%, 2%, 5% glycerol). In certain embodiments, the choline salt is selected from choline bicarbonate and choline hydroxide.
- In some embodiments, the salting methods involve mixing by sonication or mechanical disruption. Mixing is performed for 10 to 120 minutes; preferably 15-90 minutes; more preferably for at least 30 minutes. Mixing is carried out at a temperature between about 20° C. and about 80° C.; such as between about 20, 30 or 40° C. and about 60, 70, or 80° C.
- Salting methods of the invention optionally include a sterile filtration step. Sterile filtration can be accomplished, for example, using a 0.22 μm filter, such as a 0.22 μm syringe filter.
- Compounds of the subject invention are useful as pharmaceutical substances and particularly as vaccine adjuvants (i.e. as immunostimulants). The invention provides a pharmaceutical composition or a vaccine composition or an immunogenic composition comprising a compound of the invention. Such compositions typically comprise a suitable diluent or carrier, such as water. The composition may be prepared in dry form for making up with water prior to administration. Such compositions may be based on a liposome or other nanoparticle composition in which the compound of the invention is dispersed or an oil in water composition in which the compound of the invention is dispersed. Such compositions may contain other immunostimulants including saponins such as QS21, lipopolysaccharides including MPL and 3D-MPL, CpG oligonucleotides, other TLR7 and TLR8 agonists (such as imiquimod or resiquimod) and combinations thereof.
- Such compositions typically contain a vaccine antigen (or more than one). Exemplary antigens include disease antigens including antigens derived from pathogens including viruses (such as HIV, HAV, HBV, HCV, HPV, influenza, human rhinovirus, human syncytial virus), bacteria (such as Corynebacterium diphtheria, Bordetella pertussis, Clostridium tetani and toxins secreted thereby, Mycobacterium tuberculosis, Neisseria spp., Meningococcus spp., Chlamydia spp.), and protozoa (such as Plasmodium spp.) which cause infectious diseases and cancer antigens (such as MAGE).
- In a specific embodiment, the antigen is an influenza antigen e.g. a split influenza antigen such as a pandemic influenza antigen.
- In a specific embodiment the antigen is a polysaccharide antigen or a polysaccharide containing antigen.
- In further embodiments the compounds of the invention may be administered orally in the form of capsules. In other embodiments the compounds of the invention may be administered topically to a skin or mucosal surface. In such embodiments the compounds of the invention may be combined with conventional topically acceptable diluents.
- The invention provides a method of inducing an immune response in a mammal which comprises administering to a mammal in need thereof an immunostimulatory amount of a compound of the invention or a composition containing it (for example a composition described above). The invention also provides a compound of the invention or a composition containing it (for example a composition described above) for use in inducing an immune response in a mammal. The invention also provides use of a compound of the invention or a composition containing it (for example a composition described above) in the manufacture of a medicament for inducing an immune response in a mammal.
- The induced immune response may include induction of a
type 1 interferon response and/or inducing pro-inflammatory cytokines such as IFN-α and IFN-γ as well as IL-12 and TNF-α. - The invention also provides a method of inducing protective immunity against a disease in a mammal which comprises administering to a mammal in need thereof an immunostimulatory amount of a compound of the invention together with a disease antigen. Disease antigens include antigens derived from pathogens including viruses, bacteria and protozoa which cause infectious diseases mentioned above. The invention also provides a composition comprising a compound of the invention and a disease antigen for use in inducing protective immunity against a disease in a mammal. The invention also provides use of a composition comprising a compound of the invention and a disease antigen in the manufacture of a medicament for inducing protective immunity against a disease in a mammal.
- The invention also provides a method of treatment or prophylaxis of cancer in a mammal which comprises administering to a mammal in need thereof an immunostimulatory amount of a compound of the invention together with a cancer antigen. Cancer antigens include antigens associated with or derived from cancers mentioned above. The invention also provides a composition comprising a compound of the invention and a cancer antigen for use in the treatment or prophylaxis of cancer in a mammal. The invention also provides use of a composition comprising a compound of the invention and a cancer antigen in the manufacture of a medicament for the treatment or prophylaxis of cancer in a mammal.
- An immunostimulatory amount of a compound of the invention may be between 1 μg and 2 mg, although this amount is illustrative and non-limiting. Thus a vaccine composition may, for example, comprise antigen and 1 μg to 2 mg of a compound of the invention.
- The compounds of the invention are expected to have one or more of the following favourable attributes: good agonist activity at hTLR7 and/or hTLR8 (preferably hTLR7 and hTLR8); favourable ratio of TLR7/8 agonist activity; good activity at inducing cytokines e.g. IFN-α, IFN-γ and/or TNF-α, low toxicity; and good chemical and physical stability.
- Throughout the specification and the claims which follow, unless the context requires otherwise, the word ‘comprise’, and variations such as ‘comprises’ and ‘comprising’, will be understood to imply the inclusion of a stated integer, step, group of integers or group of steps but not to the exclusion of any other integer, step, group of integers or group of steps.
- p-TsOH p-toluenesulfonic acid
p-TsCl p-toluenesulfonyl chloride
THP tetrahydropyran
TBS t-butyldimethylsilyl
HIV human immunodeficiency virus
HAV hepatitis A virus
HBV hepatitis B virus
HCV hepatitis C virus
HPV human papilloma virus
IFN interferon - Lev levulinoyl
TEA triethylamine
CE cyanoethyl
Imid imidazolium
OTf triflate
nBu n-butyl
i-Pr isopropyl
Bn benzyl
t-Bu t-butyl
MeCN acetonitrile
Eq equivalent
M molar
h hour
rt room temperature -
- A compound of formula (VIII) (2.0 eq) and 2-cyanoethyl N,N,N′,N′-tetraisopropylphosphordiamidite (2.1 eq) were dissolved in anhydrous methylene chloride (0.4 M) at rt. 1H-tetrazole (2.1 eq) was added in four portions over 20 min and the reaction mixture stirred at rt for 1 h. The reaction mixture was cooled to 0° C., imidazoquinoline of formula (II) (1.0 eq) and imidazolium triflate (1.5 eq) were added, and the reaction mixture allowed to warm up to rt. The reaction was usually completed after 1 h at rt and the reaction mixture was purified by chromatography on silica gel (after reducing the volume by concentration under vacuum). The resulting phosphite (I*) was dissolved in chloroform (0.07 M) and oxidized by addition of t-butyl hydroperoxide (1.5 eq). After stirring at rt for 30 min, the reaction mixture was concentrated under vacuum. The levulinoyl group was subsequently deprotected by reacting (I*) in a 4:1 mixture of pyridine:acetic acid (0.05 M) with hydrazine hydrate (5.0 eq). After 5-10 min ar rt, the reaction mixture was cooled to 0° C. and stirred with 2,4-pentanedione (10.0 eq) at 0° C. for 5 min. After aqueous work-up, the dried crude was dissolved in acetonitrile (0.06 M). Triethylamine (acetonitrile:TEA 1:0.35 v:v) was added and the reaction mixture stirred at rt for 6 to 18 h. Once the deprotection was complete, the reaction mixture was filtered over a Büchner filter and the isolated solid rinsed with acetonitrile and dried under high vacuum, or purified by chromatography on silica gel to give compound of formula I.
-
- This compound was prepared by following the method of
Scheme 3. - C1 was coupled with 1,2-dioleoyl-sn-glycerol following the procedure described in
General Procedure 1. After purification by chromatography on silica gel (0 to 10% methanol in chloroform), the corresponding phosphite (I*) was isolated in 66% yield. (I*) was subsequently oxidized with t-butyl peroxide and deprotected sequentially with hydrazine hydrate and TEA as described inGeneral procedure 1 to give Example 1 in 84% yield. 1H NMR (400 MHz, CDCl3/CD3OD) δ 7.84 (d, 1H), 7.24 (m, 2H), 5.33 (m, 4H), 5.27 (m, 1H), 4.8 (m, 2H), 4.43 (dd, 1H), 4.39 (m, 2H), 4.22 (dd, 1H), 4.10 (t, 2H), 3.99 (t, 2H), 2.92 (t, 2H), 2.32 (m, 4H), 2.00 (m, 8H), 1.84 (m, 2H), 1.60 (m, 4H), 1.51 (m, 2H), 1.30 (m, 40H) 1.02 (t, 3H), 0.88 (m, 6H); negative ES TOF-MS calc for [M−H]− 1025.67, found 1025.72. -
- This compound was prepared by following the method of
Scheme 4. - Cwas coupled with 1,2-dipalmitoyl-3-triethyleneglycol-sn-glycerol following the procedure described in
General Procedure 1. After purification by chromatography on silica gel (0 to 10% methanol in chloroform), the corresponding phosphite (I*) was not isolated clean. Crude (I*) was subsequently oxidized with t-butyl peroxide and the resulting oxidized (I*), obtained in 51% yield after purification by chromatography on silica gel (0 to 15% methanol in chloroform), was deprotected sequentially with hydrazine hydrate and TEA as described inGeneral procedure 1 to give Example 2 in 61% yield after chromatography on silica gel (0 to 40% methanol in chloroform). 1H NMR (400 MHz, CDCl3/CD3OD) δ 7.79 (d, 1H), 7.11 (bs, 2H), 5.21 (m, 1H), 4.49 (t, 2H), 4.34 (m, 5H), 4.07-4.16 (m, 3H), 4.01 (t, 2H), 3.72 (t, 2H), 3.60-3.66 (m, 11H), 2.91 (t, 2H), 2.30 (dd, 4H), 1.82 (m, 2H), 1.60 (m, 4H), 1.50 (m, 2H), 1.25 (m, 45H), 1.01 (t, 3H),0.88 (t, 6H); Positive ES TOF-MS calc for [M+H]+ 1107.7338, found 1107.6374. -
- This compound was prepared by following the method of
Scheme 5. - C1 was coupled with 1-palmitoyl-2-tetrahydropyranyl-sn-glycerol following the procedure described in
General Procedure 1. After purification by chromatography on silica gel (0 to 10% methanol in chloroform), the corresponding phosphite (I*) was isolated in 34% yield. (I*) was subsequently oxidized with t-butyl peroxide and deprotected sequentially with hydrazine hydrate and TEA as described inGeneral procedure 1 to give the corresponding THP protected intermediate in 85% yield. The THP protecting group was removed by reaction in 1:1 chloroform: methanol (0.02 M) with 4 N HCl/dioxane (2.5 eq) at 0° C. for 3 h. After 3 h, the reaction mixture was dried under vacuum and purified by chromatography on silica gel (0 to 25% methanol/water 95/5 in chloroform) to give Example 3 in 92% yield. 1H NMR (400 MHz, CDCl3/CD3OD) δ 7.85 (d, 1H), 7.26 (m, 2H), 5.34 (m, 2H), 4.50 (m, 4H), 4.39 (m, 2H), 4.13 (m, 2H), 4.02 (m, 5H), 2.91 (t, 2H), 2.32 (t, 2H), 2.00 (m, 4H), 1.83 (p, 2H), 1.60 (m, 2H), 1.50 (m, 2H), 1.27 (m, 20H), 1.02 (t, 3H), 0.88 (t, 3H); negative ES TOF-MS calc for [M−H]− 761.91, found 761.71. -
- This compound was prepared by following the method of
Scheme 6. - C1 was coupled with cholesterol triethyleneglycol following the procedure described in
General Procedure 1. After purification by chromatography on silica gel (0 to 10% methanol in chloroform), the corresponding phosphite (I*) was isolated in 37% yield. (I*) was subsequently oxidized with t-butyl peroxide and after purification by chromatography on silica gel (0 to 10% methanol in chloroform), the oxidized phosphite (obtained in 53% yield) was deprotected sequentially with hydrazine hydrate and TEA as described inGeneral procedure 1 to give Example 4 in 71% yield. 1H NMR (400 MHz, CDCl3/CD3OD) δ 7.71 (d, 1H), 6.95 (bs, 2H), 5.30 (m, 1H), 4.47 (m, 2H), 4.24 (bs, 4H), 4.07 (m, 2H), 4.02 (m, 2H), 3.71 (t, 2 H), 3.63-3.66 (m, 9H contains H2O), 3.15 (m, 1H), 2.91 (t, 2H), 2.33 (dd, 1H), 2.18 (t, 1H), 1.77-2.00 (m, 7H), 1.20-1.68 (m, 20H), 0.81-1.15 (m, 23H), 0.65 (s, 3H); negative ES TOF-MS calc for [M−H]− 923.5663, found 923.6067. -
- This compound was prepared by following the method of
Scheme 7. - C2 was coupled with 1,2-dioleoyl-sn-glycerol following the procedure described in
General Procedure 1. After purification by chromatography on silica gel (0 to 10% methanol in chloroform), the corresponding phosphite (I*) was isolated in 74% yield. (I*) was subsequently oxidized with t-butyl peroxide and deprotected sequentially with hydrazine hydrate and TEA as described inGeneral procedure 1 to give Example 5 in 79% yield after chromatography on silica gel (0 to 15% methanol/water 95/5 in chloroform). 1H NMR (400 MHz, CDCl3/CD3OD) δ 7.90 (d, 1H), 7.65 (s, 1H), 7.02 (d, 1H), 5.34 (m, 4H), 5.26 (m, 1H), 4.58 (t, 2H), 4.41 (dd, 1H), 4.29 (t, 2H), 4.19 (dd, 1H), 4.1 (m, 4H), 4.00 (t, 2H), 2.98 (t, 2H), 2.30 (m, 4H), 2.00 (m, 10H), 1.89 (m, 2H), 1.80 (m, 2H), 1.58 (m, 4H), 1.51 (m, 2H), 1.29 (m, 40H), 1.03 (t, 3H), 0.88 (m, 6H); negative ES TOF-MS calc for [M−H]− 1053.7027, found 1053.7857. -
- This compound was prepared by following the method of
Scheme 8. - C3 was coupled with 1,2-dioleoyl-sn-glycerol following the procedure described in
General Procedure 1. After purification by chromatography on silica gel (0 to 10% methanol in chloroform), the corresponding phosphite (I*) was isolated in 75% yield. (I*) was subsequently oxidized with t-butyl peroxide and deprotected sequentially with hydrazine hydrate and TEA as described inGeneral procedure 1 to give Example 6 in 80% yield after chromatography on silica gel (0 to 15% methanol/water 9/1 in chloroform). 1H NMR (400 MHz, CDCl3/CD3OD) δ 7.91 (d, 1H), 7.4 7(s, 1H), 7.07 (d, 1H), 5.34 (m, 4H), 5.27 (m, 1H), 4.58 (t, 2H), 4.42 (dd, 1H), 4.35 (t, 2H), 4.21 (dd, 1H), 4.10 (m, 4H), 4.01 (t, 2H), 3.94 (t, 2H), 3.76 (t, 2H), 3.72 (t, 2H), 3.64 (t, 2H), 2.98 (t, 2H), 2.31 (m, 4H), 2.01 (m, 8H), 1.88 (m, 2H), 1.50 (m, 6H), 1.29 (m, 40H), 1.03 (t, 3H), 0.88 (m, 6H); negative ES TOF-MS calc for [M−H]− 1113.7232, found 1113.8110. -
- This compound was prepared by following the method of
Scheme 9. - C1 was coupled with 1,2-dipalmitoyl-sn-glycerol following the procedure described in
General Procedure 1. After purification by chromatography on silica gel (0 to 12% methanol in chloroform), the corresponding phosphite (I*) was isolated in 67% yield. (I*) was subsequently oxidized with t-butyl peroxide and deprotected sequentially with hydrazine hydrate and TEA as described inGeneral procedure 1 to give Example 7 in 68% yield after purification by chromatography on silica gel (0 to 15% methanol/water 9/1 in chloroform). 1H NMR (400 MHz, CDCl3/CD3OD) δ 7.83 (d, 1H), 7.26 (m, 2H), 5.26 (m, 1H), 4.50 (m, 7H), 4.21 (dd, 1H), 4.09 (t, 2H), 4.00 (t, 2H), 2.91 (t, 2H), 2.31 (m, 4H), 1.83 (m, 2H), 1.5 (m, 6H), 1.25 (m, 48H), 1.02 (t, 3H), 0.88 (m, 6H); negative ES TOF-MS calc for [M−H]− 973.64, found 963.65. -
- This compound was prepared following known literature procedure (Gerster et al. J. Med. Chem., 2005, 48, 3481).
-
- This compound was prepared by following the method of
Scheme 10. - Di-oleoyl-sn-glycerol (2.0 eq) and 2-cyanoethyl N,N,N′,N′-tetraisopropylphosphordiamidite (1.5 eq) were dissolved in anhydrous chloroform (0.4 M) at rt. 1H-tetrazole (1.5 eq) was added in four portions over 20 min and the reaction mixture stirred at rt for 2 h. The reaction mixture was cooled to 0° C., Comparative Example 1 (1.0 eq) and imidazolium triflate (2.0 eq) were added, and the reaction mixture allowed to warm up to rt. The reaction was complete after 1 h at rt and the reaction mixture was purified by chromatography on silica gel (0 to 15% methanol in chloroform) to give the corresponding phosphite in 92% yield. The phosphite was dissolved in chloroform (0.07 M) and oxidized by addition of t-butyl hydroperoxide (2.0 eq). After stirring at rt for 30 min, the reaction mixture was concentrated under vacuum. The dried crude was dissolved in acetonitrile (0.08 M). Triethylamine (acetonitrile:TEA 1:0.35 v:v) was added and the reaction mixture stirred at rt for 15 h then dried under vacuum. Purification by chromatography on silica gel (0 to 15% methanol in chloroform) gave Comparative Example 2 in 75% yield. 1H NMR (400 MHz, CDCl3/CD3OD) δ 8.18 (bs, 1H), 7.39 (bs, 1H), 7.18 (bs, 1H), 6.92 (bs, 1H), 5.33 (m, 4H), 5.25 (m, 1H), 4.80 (bs, 2H), 4.60 (bs, 2H), 4.41 (dd, J=3.2, 12.0 Hz, 1H), 4.19 (dd, J=6.4, 12.0 Hz, 1H), 4.03 (t, J=6.0 Hz, 2H), 3.01 (bs, 2H), 2.30 (m, 4H), 1.98 (m, 4H), 1.57 (m, 6H), 1.27 (m, 40H), 1.05 (t, J=7.2, 3H), 0.88 (m, 6H); negative ES TOF-MS calc for [M−H]− 965.6497, found 965.6498.
-
- This compound was prepared by following the method of Scheme 11.
- Concentrated nitric acid (70% content, 1.5 eq) was very slowly added to a solution of C4 in propionic acid (0.37 M) heated to 125° C. The reaction mixture was stirred 3 h at 125° C., allowed to cool to rt and filtered on filter paper. The collected solid was rinsed with water and dried under vacuum to give C5 in 74% yield.
A solution of POCl3 (1.2 eq) in DMF (1.6 M), prepared by dropwise addition of POCl3 to cold (0° C.) DMF and stirring for 30 min at 0° C., was slowly added to a suspension of C5 in DMF (0.45 M). At the end of the addition, the reaction mixture was heated to 100° C. for 5 min, cooled to rt and poured into ice water. The resulting precipitate was filtered and dried under vacuum overnight. The dried solid was dissolved in chloroform (0.4 M) and TEA (1.4 eq) and ethanolamine (1.2 eq) were added and the reaction mixture stirred at 40° C. for 1 h then at rt for 4 h. The reaction mixture was concentrated under vacuum, and the dried solid washed with water, filtered, dried, triturated with hot ethyl acetate to give C6 in 94% yield. 1H NMR (400 MHz, CD3OD) δ 9.31(s, 1H), 8.22 (d, 1H), 7.3 (m, 6H), 7.17 (dd, 1H), 5.23 (s, 2H), 4.05 (t, 2H), 3.85 (t, 2H).
C6 was dissolved in 1:1 solution of chloroform:methanol (0.01 M) and hydrogenated with 10% Pd/C using a ThalesNano H-Cube (full H2, 40-60° C.). The hydrogenated solution was concentrated, dried under vacuum and purified by chromatography on silica gel to give C7 and C7a in 21% and 41% yield, respectively. C7: LC-MS [M+H]+ 310.13; C7a: LC-MS [M+H]+ 220.08.
p-TsOH (0.2 eq) was added to a suspension of C7a in toluene (0.15 M) and the suspension heated to 60° C. Trimethylorthovalerate (2 eq) was dropwise added and the mixture stirred at 60° C. for 5 h. After cooling to rt, the reaction mixture was concentrated, dried under vacuum and purified by chromatography on silica gel (5 to 40% methanol in chloroform). Fractions containing the desired product were dried and recrystallized from chloroform/methanol/ethyl acetate to give C8 in 42% yield.
Cesium carbonate (3 eq) was added to a solution of C8 in DMF (0.18 M) at 0° C., A solution of acetyl protected bromoethanol in DMF (1.2 eq, 1.3 M) was then added dropwise and the reaction mixture stirred at 0° C. for 10 min then allowed to warm up to rt. After stirring overnight at rt and aqueous work-up, the dried crude was purified by chromatography on silica gel (0 to 15% methanol in chloroform) to give C9 in 77% yield.
Peracetic acid (1.2 eq) was added to a suspension of C9 in reagent ethanol (0.08 M) and the reaction mixture heated to 60° C. for 2.5 h. Additional peracetic acid (0.1 eq) was added and the reaction mixture heated to 60° C. for another 6 h. After concentration and drying under vacuum, the crude was purified by chromatography on silica gel (0 to 35% methanol in chloroform) to give the corresponding N-oxide intermediate in 73% yield. p-TsCl (1.1 eq) was slowly added to a suspension of N-oxide in aqueous concentrated ammonia (0.3 M) and the reaction mixture stirred at rt for 30 min. More p-TsCl (0.9) was added and after 30 min at rt, the reaction mixture was quenched with water. After aqueous work-up, the crude was purified by chromatography on silica gel (0 to 25% methanol in chloroform) to give Comparative Example 3 as an off-white solid in 46% yield. 1H NMR (400 MHz, CD3OD) δ 8.25 (d, 1H), 7.28 (m, 2H), 4.78 (t, 2H), 4.21 (t, 2H), 4.03 (t, 2H), 3.95 (t, 2H), 3.16 (t, 2H), 1.98 (m, 2H), 1.56 (m, 2H), 1.05 (t, 3H); Positive ES TOF-MS calc for [M+H]+ 345.1927, found 345.2241. -
- This compound was prepared by following the method of Scheme 12.
- p-TsOH (0.2 eq) was added to a suspension of C7 in toluene (0.15 M) and the suspension heated to 60° C. Trimethylorthovalerate (2 eq) was dropwise added and the mixture stirred at 60° C. for 5 h. More trimethylorthovalerate was added as needed to push the reaction to completion. After cooling to rt, the reaction mixture was filtered, the precipitate washed with ethyl acetate and dried to give C10 as a light brown solid in 97% yield. Levulininc acid (1.2 eq) was added to a suspension of C10 in anhydrous methylene chloride (0.27 M). The reaction mixture was cooled to 0° C. and DMAP (0.02 eq) and DCC (1.05 eq) were added. After 10 min at 0° C. followed by 40 min at rt, the reaction mixture was adsorbed on silica gel and purified by chromatography on silica gel (0 to 8% methanol in chloroform) to give C11 in 66% yield.
Peracetic acid (1.2 eq) was added to a suspension of C11 in reagent ethanol (0.16 M) and the reaction mixture heated to 60° C. for 3 h. After concentration and drying under vacuum, the crude was triturated with hot ethyl acetate, filtered and dried to give the corresponding N-oxide intermediate in 83% yield. Aqueous ammonia (1:3 ammonia:methylene chloride) was added to a solution of N-oxide in methylene chloride (0.2 M). p-TsCl (1.1 eq) was slowly added and the reaction mixture stirred at rt for 30 min then quenched with water. After aqueous work-up, the dried crude dissolved in 1:1 chloroform:methanol was hydrogenated on 10% Pd/C using a ThalesNano H-Cube (60° C., full H2 mode). The hydrogenated solution was concentrated, dried under vacuum, and purified by chromatography on silica gel (0 to 15% methanol in chloroform) to give C12 in 88% yield.
Cesium carbonate (3 eq) was added to a solution of C12 in DMF (0.2 M) at 0° C., A solution of TBS protected bromobutanol in DMF (1.2 eq, 1.3 M) was then added dropwise and the reaction mixture stirred at 0° C. for 10 min then at rt for 7 h then quenched with water. After aqueous work-up, the dried crude was purified by chromatography on silica gel (0 to 10% methanol in chloroform) to give C13 in 78% yield.
A solution of C13 in 1:1 chloroform:methanol (0.016 M) was hydrogenated on 10% Pd/C using a ThalesNano H-Cube (rt, full H2 mode). The hydrogenated solution was concentrated, dried under vacuum, and purified by chromatography on silica gel (0 to 15% methanol in chloroform) to give C14 in 66% yield.
A solution of C14 in a 4:1 mixture of pyridine:acetic acid (0.05M) was reacted with hydrazine hydrate (5.0 eq). After 5-10 min at rt, the reaction mixture was cooled to 0° C. and stirred with 2,4-pentanedione (10.0 eq) at 0° C. for 5 min. After aqueous work-up, the dried solid was salted with concentrated HCl and recrystallized from methanol/ethyl acetate to give Comparative Example 4 in 78% yield. 1H NMR (400 MHz, CD3OD) δ 8.20 (d, 1H), 7.21 (m, 2H), 4.70 (t, 2H), 4.17 (t, 2H), 4.01 (t, 2H), 3.65 (t, 2H), 3.05 (t, 2H), 1.93 (m, 4H), 1.75 (m, 2H), 1.54 (hex, 2H), 1.04 (t, 3H), Positive ES TOF-MS calc for [M+H]+ 345.1927, found 345.2241. -
- This compound was prepared by following the method of Scheme 13.
- Cesium carbonate (3 eq) was added to a solution of C12 in DMF (0.1 M) at 0° C., A solution of triethyleneglycol bromide in DMF (1.2 eq, 1.3 M) was then added dropwise and the reaction mixture stirred at 0° C. for 10 min then at rt for 17 h then quenched with water. After aqueous work-up, the dried crude was purified by chromatography on silica gel (0 to 30% methanol in chloroform) to give Comparative Example 5 in 13% yield. 1H NMR (400 MHz, CD3OD) δ 8.20 (d, 1H), 7.21 (m, 2H), 4.70 (t, 2H), 4.17 (t, 2H), 4.01 (t, 2H), 3.65 (t, 2H), 3.05 (t, 2H), 1.93 (m, 4H), 1.75 (m, 2H), 1.54 (hex, 2H), 1.04 (t, 3H); Positive ES TOF-MS calc for [M+H]+ 433.2451, found 433.2816.
- This compound was prepared by following the method of Scheme 14.
- Cesium carbonate (6 eq) was added to a solution of C12 in DMF (0.11 M) at 0° C., A solution of TBS protected bromoethanol in DMF (1.2 eq, 0.4 M) was then added dropwise and the reaction mixture stirred at 0° C. for 10 min then allowed to warm up to rt. After stirring at rt or 5 h and aqueous work-up, the dried crude was purified by chromatography on silica gel (0 to 5% methanol in chloroform) to give C14 in 59% yield. LC-MS: [M+H]+ 557.3.
20 eq of TFA were added to a solution of C14 in methylene chloride (0.18 M) and the reaction mixture stirred at rt for 4 h. After drying under vacuum and purification by chromatography on silica gel (0 to 20% methanol in chloroform), C1 (TFA salt) was obtained in 83% yield. - To improve the solubility of the lipidated imidazoquinoline derivatives (IQs) described herein, a salt screening study was performed. For this study, acid salts tested included naphthalene-1,5-disulfonic acid; benzenesulfonic acid; HCl; and 2-naphthalenesulfonic acid. Basic salts tested included choline bicarbonate, choline hydroxide, TRIS; Ethylene diamine; and N-methylglucamine.
With the exception of choline salts, none of the salts tested had a significant effect on solubility of the IQ compound. In addition, LCMS revealed that choline salt forms of IQ generally exhibited less degradation during the drying process than the other salts tested. Based on the salt screening results, choline bicarbonate and chlorine hydroxide salts were selected for further formulation process development. - During the salt screening experiments described above, it was observed that the solvent removal steps could impair recovery of the salted IQ compound. Specifically, increased drying times resulted in lower solubility and increased degradation of the IQ compound. It was surprisingly discovered that acceptable solubility and stability can be achieved by either avoiding the use of organic solvents (Direct Aqueous Salting Method), or decreasing the drying time required to remove the solvent (Dry Salting Method).
FIG. 18 is a schematic representation of the prior art salting method (A), and the two novel salting methods (B—Direct Aqueous method; C—Dry Salting method). - IQ compound salts were prepared according to methods known in the art. Briefly, lipidated imidazoquinoline derivatives (IQ) are dissolved in tetrahydrofuran (THF). Acid or base salts are dissolved in methanol, and added to the dissolved IQ. Solvents are then removed by evaporation using a rotary evaporator, followed by additional drying under high vacuum at room temperature for 1-19.5 hours. After solvent evaporation, a 2% glycerol in water solution is added to the salted compound and sonicated for 15 minutes with a probe sonicator. The salted formulation is then sterile filtered with a 0.22 um syringe filter. Concentration of the IQ salts is determined by RP-HPLC, and product identity is confirmed by liquid chromatography-mass spectrometry (LCMS).
- Salts of the compounds of Examples 1-7 were prepared according to the following methods. First, the lipidated imidazoquinoline derivative (IQ) was dissolved dirtectly in an aqueous vehicle (2% glycerol in water). A choline salt, either choline bicarbonate or choline hydroxide, was added directly to the dissolved IQ compound in amounts of 0.6, 0.8, 1 and 1.2 molar equivalents (EQ). The solution was then sonicated for 15-90 minutes with a probe sonicator at a temperature of 60-80° C. The salted formulation was sterile filtered with a 0.22 um syringe filter.
Choline salts of the compounds of Examples 1-7 were at least as soluble as compounds prepared by the prior art salting procedure, but surprisingly had significantly less degradation than IQ salts prepared by the prior art method. Furthermore, the direct aqueous process can be carried out in less time than the prior art method, and avoids the use of organic solvents. Similar results were observed for salted compounds made with 0.6, 0.8 and 1.2 EQ choline salts.
These results indicate that direct aqueous salting is an advantageous method for use with the IQ compounds described herein. - Salts of the compounds of Examples 1-7 were prepared according to the following methods. First, the lipidated imidazoquinoline derivative (IQ) was dissolved in tetrahydrofuran (THF). A choline salt, either choline bicarbonate or choline hydroxide, was added directly to the dissolved IQ compound in amounts up to 4 molar equivalents (EQ). The THF solvent was then removed by evaporation using a rotary evaporator. Vacuum drying was not performed. After solvent evaporation, a 2% glycerol in water solution was added to the salted compound and sonicated for 15 minutes with a probe sonicator. The salted formulation was then sterile filtered with a 0.22 um syringe filter.
Choline bicarbonate and choline hydroxide salts of the compounds of Examples 1-7 were found to exhibit better solubility and stability as compared to the unsalted formulation, indicating that the dry salting method is an advantageous method for use with the IQ compounds described herein. - Determination of TLR agonist activity was performed using the HEK293 binding assay. This assay measures TLR7 and TLR8 selectivity and potency of the compounds tested. HEK293 cells expressing human TLR7 or TLR8 and NFKB responsive Secreted Embryonic Alkaline Phosphatase (SEAP) reporter gene were obtained from InvivoGen (San Diego, Calif.). These cells were maintained in culture media of Dulbecco's Modified Eagle Medium (DMEM) (Invitrogen, Grand Island, N.Y.), 10% Fetal Bovine Serum (FBS) (Sigma, St. Louis, Mo.) and selection antibiotics (Invitrogen, and Invivogen). HEK293 stably transfected with human TLR7 (hTLR7) or human TLR8 (hTLR8) were stimulated for 24 h with aqueous formulations of test compounds and culture supernatants were analyzed for NFKB activation using the colorimetric SEAP detection kit QuantBlue (InvivoGen).
- Test compounds were evaluated for cytokine induction in human peripheral blood mononuclear cells (hPBMCs).
- Primary human PBMCs were isolated from fresh blood from healthy donors via Ficoll gradient separation and plated at 0.5×106 cells/well in 96-well tissue culture plates (RPMI-1640 plus 10% FBS). hPBMCs were maintained with RPMI-1640 culture media (Invitrogen, Grand Island, N.Y.), antibiotics (Invitrogen) and 10% FBS (Sigma).
- hPBMCs were stimulated for 24 h with aqueous formulations of test compounds. Culture supernatants were analyzed for TNF-α and IFN-γ induction using multiplex kits (FluoroKine multiplex kits from R&D Systems, Minneapolis, Minn.) and for IFN-α induction using human IFN-α VeriKine ELISA kit (Pestka Biomedical Laboratories, Inc., Piscataway, N.J.).
- Comparative Examples 1, 2 and 3 and Example 1 were tested for their hTLR7 and hTLR8 agonist activity and the results are shown in
FIGS. 1 and 2 and summarised in Table 1 below. -
TABLE 1 Comp Ex Comp Ex Comp Ex 1 2 3 Ex 1hTLR7 0.58 34.58 1.56 1.06 ED50 (μM) hTLR8 0.19 25.99 0.10 0.10 ED50 (μM) hTLR7/8 3.1 1.3 15.5 11.0 ratio - The results show that Example 1 demonstrates notable selectivity for hTLR8/hTLR7 and is significantly more potent as an agonist of hTLR7 and hTLR8 than Comparative Example 2 in this reporter assay.
- On another occasion, Comparative Examples 1, 2 and 3 and Examples 1, 3 and 4 were tested for their hTLR7 and hTLR8 agonist activity and the results are shown in
FIGS. 3 and 4 and summarised in Table 2 below. -
TABLE 2 Comp Ex Comp Ex Comp Ex 1 2 3 Ex 1Ex 3Ex 4hTLR7 1.0 55.4* 2.4 7.0 3.4 — ED50 (μM) hTLR8 0.4 39.2* 0.8 0.8 2.8 31.9 ED50 (μM) hTLR7/8 2.3 1.4 2.9 8.9 1.2 — ratio *only very low levels of NFκB activation were detected - The results confirm that Example 1 is more active than Comparative Example 2 as an agonist of hTLR7 and hTLR8. Example 3 is also a potent agonist of hTLR7 and hTLR8, being approximately equally potent at both receptors in this reporter assay. Example 4 was a weaker agonist of hTLR8 and did not agonise hTLR7 in this reporter assay.
- On another occasion, Comparative Examples 1, 3, 4 and 5 and Examples 1, 5, and 6 were tested for their hTLR7 and hTLR8 agonist activity and the results are shown in
FIGS. 5 and 6 and summarised in Table 3 below. -
TABLE 3 Comp Comp Comp Comp Ex 1 Ex 3Ex 4Ex 5Ex 1Ex 5Ex 6hTLR7 1.1 2.2 1.6 13.2 4.1 10.5* 8.7* ED50 (μM) hTLR8 0.72 1.1 2.2 16.3 0.59 6.6* 5.8 ED50 (μM) hTLR7/8 1.5 1.9 0.7 0.8 6.9 1.6 1.5 ratio *only very low levels of NFκB activation were detected - The results confirm that Example 1 is an agonist of both TLR7 and TLR8.
- Example 5 was a very weak agonist of hTLR7 or hTLR8 in this reporter assay. Comparative Example 4 was a good agonist of hTLR7 and hTLR8 but Comparative Example 5 was a quite weak agonist of hTLR7 and hTLR8 in this reporter assay. Example 6 was a reasonably potent agonist of hTLR8 in this reporter assay but was a very weak agonist of hTLR7 in this reporter assay.
- On another occasion, Comparative Example 1 and Examples 1, 2, and 7 were tested for their TLR7 and TLR8 agonist activity and the results are shown in
FIGS. 7 and 8 and summarised in Table 4 below. -
TABLE 4 Comp Ex 1Ex 1Ex 2Ex 7hTLR7 1.5 7.0 6.1 14.6 ED50 (μM) hTLR8 0.61 0.71 0.81 3.81 ED50 (μM) hTLR7/8 2.4 9.9 7.5 3.8 ratio - The results for Example 1 were similar to those presented in Table 1, 2 and 3 above. Example 2 showed a similar profile to that of Example 1 in that it was significantly more potent as an agonist of hTLR8 than hTLR7. Example 7 was also an agonist of hTLR7 and hTLR8 but less potent than Examples 1 and 2, particularly at hTLR8.
- Comparative Examples 1, 2 and 3 and Example 1 were tested for their activity in inducing IFN-γ and IFN-α in hPBMCs and the results are shown in
FIGS. 9 and 10 . - Example 1 was more potent than Comparative Example 3 but less potent than Comparative Example 1 at inducing IFN-γ but in this assay. Comparative Example 2 did not induce any IFN-γ in this assay.
- Example 1 and Comparative Example 3 were equipotent at inducing IFN-α and these were more potent than Comparative Example 1 and Comparative Example 2 in this assay at a lower dose.
- On another occasion Comparative Examples 1, 2 and 3 and Examples 1, 3 and 4 were tested for their activity in inducing IFN-γ, IFN-α and TNF-α in hPBMCs and the results are shown in
FIGS. 11, 12 and 13 . - Examples 1 and 3 were potent at inducing IFN-γ and each was more potent than Comparative Example 3 in this assay. Comparative Example 1 was the most potent at inducing IFN-γ in this assay. Example 4 and Comparative Example 2 did not induce IFN-γ in this assay
- Example 4 was very potent at inducing IFN-α at a higher dose, being significantly more potent than Examples 1 and 3 in this assay. These three Example compounds were all more potent at inducing IFN-α than Comparative Examples 1, 2 and 3 in this assay. The results for Example 4 were interesting considering that this compound was not active in the HEK hTLR7 reporter assay. It may be that this compound preferentially signals through the IRF-7 pathway.
- Examples 1 and 3 and Comparative Example 3 were all potent at inducing TNF-α in this assay. Comparative Example 1 also was potent at inducing TNF-α in this assay. Comparative Example 2 and Example 4 were not significantly effective at inducing TNF-α in this assay.
- On another occasion, Comparative Examples 1, 3, 4 and 5 and Examples 1, 5, and 6 were tested for their activity in inducing IFN-α and TNF-α in hPBMCs and the results are shown in
FIGS. 14 and 15 . - Example 1 was very effective at inducing IFN-α in this assay, and Example 6 was also potent, but less so than Example 1. Example 5 was potent but at higher dose. Weaker effects were shown for Comparative Examples 1 and 3. Comparative Example 4 and 5 did not induce IFN-α in this assay.
- Example 1 and Comparative Examples 1, 3 and 4, were effective at inducing TNF-α in this assay. Comparative Example 5 and Example 6 were effective but less potent. Example 5 showed a very weak effect in this assay.
- On another occasion, Comparative Example 1 and Examples 1, 2 and 7 were tested for their activity in inducing IFN-α and TNF-α in hPBMCs and the results are shown in
FIGS. 16 and 17 . - Example 1, 2 and 7 demonstrated good activity in inducing IFN-α with Example 2 being the most potent IFN-α inducer. Comparative Example 1 induced little IFN-α.
- Examples 1 and 7 and Comparative Example 1 showed similar potency in inducing TNF-α. Example 2 was a weaker inducer of TNF-α.
- The results described herein show that compounds of the invention are effective at agonising hTLR7 and/or hTLR8 and at inducing cytokines and are thus expected to have useful immunostimulatory activity in vivo. They are thus potentially suitable as vaccine adjuvants.
Claims (20)
1. A compound of formula (VI)
R1a represents —O—Z—H;
Z represents (C2-C6 alkyleneO)q;
q represents an integer 1 to 6;
R2 represents H, C1-C6alkyl, C1-C6alkylamino, C1-C6alkoxy, C3-C6 cycloalkylC1-C6 alkyl, C3-C6 cycloalkylC1-C6 alkylamino, C3-C6cycloalkylC1-C6alkoxy, C1-C6 alkoxyC1-C6 alkyl, C1-C6 alkoxyC1-C6 alkylamino, C1-C6 alkoxyC1-C6 alkoxy; and
optionally terminally substituted with a hydroxyl, amino, —NHNH2, N3, —C≡CH, —COOH, or maleimido group;
R3 represents C2-C6 alkylene-OH, C2-C6 alkylene-NH2, C2-C5 alkenyl-CH2—OH or C2-C5 alkenyl-CH2—NH2;
or pharmaceutically acceptable salt thereof or a protected derivative either thereof.
2. The compound according to claim 1 wherein R2 represents H, C1-C6alkyl or C1-C6 alkoxyC1-C6 alkyl.
3. The compound according to claim 2 wherein R2 represents H, C1-C6alkyl or C1-C3 alkoxyC1-C3 alkyl;
4. The compound according to claim 3 wherein R2 represents H, n-butyl or CH3CH2OCH2—.
5. The compound according to claim 4 wherein R2 represents H.
6. The compound according to claim 4 wherein R2 represents n-butyl.
7. The compound according to claim 4 wherein R2 represents CH3CH2OCH2—.
8. The compound according to claim 1 wherein R3 represents C2-C6 alkylene-OH.
9. The compound according to claim 8 wherein R3 represents —CH2CH2OH.
10. The compound according to claim 4 wherein R3 represents C2-C6 alkylene-OH.
11. The compound according to claim 10 wherein R3 represents —CH2CH2OH.
12. The compound according to claim 1 wherein q represents an integer 1 to 3.
13. The compound according to claim 12 wherein q represents 1.
14. The compound according to claim 12 wherein q represents 3.
15. The compound according to claim 4 wherein q represents an integer 1 to 3.
16. The compound according to claim 15 wherein q represents 1.
17. The compound according to claim 15 wherein q represents 3.
18. The compound according to claim 10 wherein q represents an integer 1 to 3.
19. The compound according to claim 18 wherein q represents 1.
20. The compound according to claim 18 wherein q represents 3.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/582,176 US20220144833A1 (en) | 2016-09-07 | 2022-01-24 | Imidazoquinoline derivatives and their use in therapy |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662384618P | 2016-09-07 | 2016-09-07 | |
PCT/EP2017/072152 WO2018046460A1 (en) | 2016-09-07 | 2017-09-05 | Imidazoquinoline derivatives and their use in therapy |
US201916330599A | 2019-03-05 | 2019-03-05 | |
US17/582,176 US20220144833A1 (en) | 2016-09-07 | 2022-01-24 | Imidazoquinoline derivatives and their use in therapy |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/330,599 Division US11274115B2 (en) | 2016-09-07 | 2017-09-05 | Imidazoquinoline derivatives and their use in therapy |
PCT/EP2017/072152 Division WO2018046460A1 (en) | 2016-09-07 | 2017-09-05 | Imidazoquinoline derivatives and their use in therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220144833A1 true US20220144833A1 (en) | 2022-05-12 |
Family
ID=59901489
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/330,599 Active 2038-11-14 US11274115B2 (en) | 2016-09-07 | 2017-09-05 | Imidazoquinoline derivatives and their use in therapy |
US17/582,150 Abandoned US20220144865A1 (en) | 2016-09-07 | 2022-01-24 | Imidazoquinoline derivatives and their use in therapy |
US17/582,176 Abandoned US20220144833A1 (en) | 2016-09-07 | 2022-01-24 | Imidazoquinoline derivatives and their use in therapy |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/330,599 Active 2038-11-14 US11274115B2 (en) | 2016-09-07 | 2017-09-05 | Imidazoquinoline derivatives and their use in therapy |
US17/582,150 Abandoned US20220144865A1 (en) | 2016-09-07 | 2022-01-24 | Imidazoquinoline derivatives and their use in therapy |
Country Status (5)
Country | Link |
---|---|
US (3) | US11274115B2 (en) |
EP (1) | EP3510036B1 (en) |
BE (1) | BE1024865B1 (en) |
ES (1) | ES2893166T3 (en) |
WO (1) | WO2018046460A1 (en) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018009916A1 (en) | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
MA46535A (en) | 2016-10-14 | 2019-08-21 | Prec Biosciences Inc | SPECIFIC MODIFIED MEGANUCLEASES OF RECOGNITION SEQUENCES IN THE HEPATITIS B VIRUS GENOME |
CA3084582A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
WO2019123340A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
EP3759109B1 (en) | 2018-02-26 | 2023-08-30 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as hbv replication inhibitors |
WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
JP7296398B2 (en) | 2018-04-06 | 2023-06-22 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. | 3'3'-cyclic dinucleotide |
TWI818007B (en) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-cyclic dinucleotides |
TW202005654A (en) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2'2'-cyclic dinucleotides |
TW201945388A (en) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis B virus genome |
US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
US11203591B2 (en) | 2018-10-31 | 2021-12-21 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
US20220143061A1 (en) | 2019-03-07 | 2022-05-12 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
WO2020190762A1 (en) * | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Macromolecule-supported tlr agonists |
KR20220004637A (en) * | 2019-04-05 | 2022-01-11 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | water soluble supplements |
TW202210480A (en) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | Solid forms of a toll-like receptor modulator |
TWI751517B (en) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | Solid forms of a toll-like receptor modulator |
EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
CR20220129A (en) | 2019-09-30 | 2022-05-06 | Gilead Sciences Inc | Hbv vaccines and methods treating hbv |
CN112778372A (en) | 2019-11-11 | 2021-05-11 | 苏州泽璟生物制药股份有限公司 | Imidazoquinoline substituted phosphate agonist and preparation method and application thereof |
US20230031465A1 (en) | 2019-12-06 | 2023-02-02 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
CA3169348A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
EP3973986A1 (en) * | 2020-09-23 | 2022-03-30 | AC BioScience SA | Immunomodulatory compounds and use thereof for the treatment and/or prevention of infectious diseases |
TW202310852A (en) | 2021-05-13 | 2023-03-16 | 美商基利科學股份有限公司 | Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics |
CA3220923A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
AU2022298639A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
US11926628B2 (en) | 2021-06-23 | 2024-03-12 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101106812B1 (en) * | 2003-08-27 | 2012-01-19 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | Aryloxy and Arylalkyleneoxy Substituted Imidazoquinolines |
CA2540541C (en) * | 2003-10-03 | 2012-03-27 | 3M Innovative Properties Company | Alkoxy substituted imidazoquinolines |
EP3085373A1 (en) * | 2006-02-22 | 2016-10-26 | 3M Innovative Properties Company | Immune response modifier conjugates |
EP2341933B1 (en) | 2008-10-24 | 2017-11-22 | GlaxoSmithKline Biologicals SA | Lipidated imidazoquinoline derivatives |
ES2458355T3 (en) * | 2010-09-01 | 2014-05-05 | Novartis Ag | Adsorption of immunopotentiators on insoluble metal salts |
US10774099B2 (en) * | 2015-12-14 | 2020-09-15 | Glaxosmithkline Biologicals Sa | Phospholipidation of imidazoquinolines and oxoadenines |
ES2848648T3 (en) * | 2015-12-14 | 2021-08-11 | Glaxosmithkline Biologicals Sa | Pegylated imidazoquinolines as TLR7 and TLR8 agonists |
-
2017
- 2017-09-05 BE BE2017/5621A patent/BE1024865B1/en not_active IP Right Cessation
- 2017-09-05 US US16/330,599 patent/US11274115B2/en active Active
- 2017-09-05 EP EP17768708.4A patent/EP3510036B1/en active Active
- 2017-09-05 ES ES17768708T patent/ES2893166T3/en active Active
- 2017-09-05 WO PCT/EP2017/072152 patent/WO2018046460A1/en unknown
-
2022
- 2022-01-24 US US17/582,150 patent/US20220144865A1/en not_active Abandoned
- 2022-01-24 US US17/582,176 patent/US20220144833A1/en not_active Abandoned
Non-Patent Citations (5)
Title |
---|
"Find ETDs Home » Thesis Resources » Find ETDs" Online: "https://ndltd.org/thesis-resources/find-etds/" Accessed January 31, 2023. * |
Bartlett "Exploiting Chemical Diversity for Drug Discovery" Edited by Paul A Bartlett and Michael Entzeroth, The Royal Society of Chemistry, 2006, pages 113-118. * |
Irwin "ZINC - A Free Database of Commercially Available Compounds for Virtual Screening" J. Chem. Inf. Model. 2005, 45, 177-182. * |
Kim "PubChem in 2021: new data content and improved web interfaces" Nucleic Acids Research, 2021, Vol. 49, Database issue Published online 5 November 2020. * |
REGISTRY/ZREGISTRY (CAS REGISTRYSM) September 2016 2 pages. * |
Also Published As
Publication number | Publication date |
---|---|
EP3510036B1 (en) | 2021-07-21 |
BE1024865B1 (en) | 2018-07-31 |
US20220144865A1 (en) | 2022-05-12 |
EP3510036A1 (en) | 2019-07-17 |
US20210277038A1 (en) | 2021-09-09 |
US11274115B2 (en) | 2022-03-15 |
ES2893166T3 (en) | 2022-02-08 |
WO2018046460A1 (en) | 2018-03-15 |
BE1024865A1 (en) | 2018-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220144833A1 (en) | Imidazoquinoline derivatives and their use in therapy | |
US10882876B2 (en) | Pegylated imidazoquinolines as TLR7 and TLR8 agonists | |
EP2341933B1 (en) | Lipidated imidazoquinoline derivatives | |
AU2018259831B2 (en) | 2-amino-quinoline derivatives | |
US10344261B2 (en) | Immunomodulatory conjugates | |
US10774099B2 (en) | Phospholipidation of imidazoquinolines and oxoadenines | |
JP2013501730A (en) | Lipid-added oxoadenine derivative | |
MX2013014145A (en) | Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom. | |
EP3774806A1 (en) | Tlr7 and / or tlr8 agonists | |
Yoo | Exploration of Toll-like Receptor 7 and 8 Agonists as Potential Vaccine Adjuvants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GLAXOSMITHKLINE BIOLOGICALS SA, BELGIUM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BAZIN-LEE, HELENE G.;BURKHART, DAVID;COCHRAN, MICHAEL;AND OTHERS;SIGNING DATES FROM 20170714 TO 20170802;REEL/FRAME:058774/0853 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |